Efficacy and safety of Daratumumab for the treatment of ABO-incompatible pure red cell aplasia after allogenic HSCT: report from SFGM-TC-Reference-Cited by-同舟云学术

Efficacy and safety of Daratumumab for the treatment of ABO-incompatible pure red cell aplasia after allogenic HSCT: report from SFGM-TC

Published:2024-03-09 Issue:6 Volume:59 Page:893-895
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Longval Thomas^ORCID,Leprêtre Anne-Claire,Ravinet Aurélie,Fayard Amandine,Forcade Edouard^ORCID,Coman Tereza,Redjoul Rabah,Berceanu Ana,Buchbinder Nimrod,Berlie Guillaume,Mappoura Maria^ORCID,Giannotti Federica,Chevillon Florian,Robin Marie^ORCID,Peffault de Latour Régis,Sicre de Fontbrune Flore^ORCID, , ,

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41409-024-02202-9.pdf

Reference16 articles.

1. Zhu P, Wu Y, Cui D, Shi J, Yu J, Zhao Y, et al. Prevalence of pure red cell aplasia following major ABO-incompatible hematopoietic stem cell transplantation. Front Immunol. 2022;13:829670.

2. Aung FM, Lichtiger B, Bassett R, Liu P, Alousi A, Bashier Q, et al. Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation. Br J Haematol. 2013;160:798–805.

3. Longval T, Galimard JE, Leprêtre AC, Suarez F, Amiranoff D, Cazaux M, et al. Treatment for pure red cell aplasia after major ABO-incompatible allogeneic stem cell transplantation: a multicentre study. Br J Haematol. 2021;193:814–26.

4. Hirokawa M, Fukuda T, Ohashi K, Hidaka M, Ichinohe T, Iwato K, et al. Efficacy and long-term outcome of treatment for pure red cell aplasia after allogeneic stem cell transplantation from major ABO-incompatible donors. Biol Blood Marrow Transplant. 2013;19:1026–32.

5. Griffith LM, McCoy JP, Bolan CD, Stroncek DF, Pickett AC, Linton GF, et al. Persistence of recipient plasma cells and anti-donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation. Br J Haematol. 2005;128:668–75.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Daratumumab/erythropoietin/rituximab;Reactions Weekly;2024-04-20